RAPS Taiwan Chapter Becomes First in Asia
RAPS has announced the establishment of a new chapter in Taiwan, its first in Asia.
The Regulatory Affairs Professionals Society (RAPS) has announced the establishment of a new chapter in Taiwan, its first in Asia. The RAPS Taiwan Chapter originated as an affiliate. In making the move to become an official chapter, it will be able to offer additional resources and opportunities to the regulatory community in Taiwan.
“Regulatory professionals from Taiwan can look forward to local training and networking activities while continuing to access RAPS resources for their professional development and career progression,” said RAPS Executive Director Sherry Keramidas, PhD, FASAE, CAE.
The chapter is the latest in a series of steps expanding RAPS’ presence in Asia. Last year, RAPS opened two new offices in Asia—a Pan-Asia office in Singapore, serving the entire Asia-Pacific region, and another in Shanghai, serving the regulatory community in China—and also began working with the government of Singapore to develop and implement a new medical device regulatory affairs training program there.
Taiwan Chapter membership is open to all who reside in Taiwan and are involved in regulatory affairs, quality or other functions related to healthcare product regulation. The chapter has a web page in Mandarin Chinese as well as a Facebook page. For information about how to join and membership benefits, contact the RAPS Taiwan Chapter via the web page at http://www.raps-in-taiwan.org.tw.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
